Immediate ART refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "treatment upon diagnosis."

**Rationale**

In clinic-based studies in the United States (U.S.) and in randomized controlled trials in resource-limited settings, immediate ART initiation has been shown to reduce time to linkage to care and viral load suppression. Rapid ART initiation also may bring earlier benefits in personal health, and earlier reductions in the risk of onward transmission of HIV. For persons with acute infection, immediate ART may limit the HIV viral reservoir. Immediate ART protocols have been instituted in various U.S. clinics,[1, 2, 3] and initiating ART on the first clinic visit after HIV diagnosis has become standard of care in a number of clinics and jurisdictions, including the city of San Francisco (under the municipal "Getting to Zero" initiative [4, 5]) and New York City (in the Department of Health Sexual Health Clinics).

Immediate ART is recommended by the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV from the U.S. Department of Health and Human Services: "the Panel ... recommends initiating ART immediately (or as soon as possible) after HIV diagnosis in order to increase the uptake of ART and linkage to care, decrease the time to viral suppression for individual patients, and improve the rate of virologic suppression among persons with HIV." [6]

This Clinicians' Guide is a distillation of best practices for immediate ART initiation (and re-initiation for persons who have stopped ART) and is based on resources from San Francisco's Getting to Zero RAPID program and San Francisco General Hospital's RAPID (Rapid ART Program Initiative for HIV Diagnoses) program.[4]
Immediate ART is not appropriate for:

- Persons with certain untreated opportunistic infections (OIs), particularly central nervous system (CNS) OIs such as cryptococcal meningitis and CNS tuberculosis for whom a short period of treatment for the OI is recommended before ART initiation, to reduce risk of dangerous IRIS (immune reconstitution inflammatory syndrome); note that this is very rare in the outpatient clinic setting

- Persons with a preliminary positive rapid HIV test result who have a low pretest probability of HIV infection. For persons who fit this description (e.g., those with no discernable individual or demographic risk factors for HIV), the preliminary result is more likely to be a false positive, and clinicians should probably wait for a positive confirmatory test result before starting ART (ART can be started immediately if the confirmatory test is positive)

Persons who decline immediate ART initiation:

Patients who are not willing or ready to start ART on the first clinic visit should be followed closely and offered ART at subsequent visits; in our experience, patients who are not ready at the first visit may be ready as soon as several days later.

Intake Appointment

The immediate-ART intake appointment is a compressed version of the standard HIV intake procedure. Goals include support, counseling, HIV education, insurance enrollment or optimization, baseline lab tests, and ART start. Ideally, a specialized multidisciplinary team potentially comprising a social worker, a nurse, and a clinician meet with the patient and conduct the intake, either together or sequentially. All clinicians provide the patient with emotional support around the diagnosis of HIV (if needed), and education about HIV infection. Most intake appointments last about 1½-2 hours.

The social worker (or a benefits specialist) assists with insurance enrollment or optimization (including access to prescription medications) and addresses any immediate needs for stabilization.

The nurse provides HIV and other clinical education and provides an overview of the clinic and of HIV care.

The clinician takes the patient’s history and performs an assessment in a condensed format, with goals of:

- Obtaining enough history to form a decision about whether to start ART and what ARV medications to use

- Beginning education about HIV, ART (including the possible benefits of early ART and why adherence is important), and preventing transmission to others (including via viral suppression on ART [U=U])

- Obtaining consent from the patient to start ART immediately

- Engaging the patient to return to clinic for follow-up appointments

Baseline laboratory testing

- Confirmatory HIV testing (if needed)

- HIV RNA (viral load)

- CD4 cell count

- HIV genotype, including integrase

- HLA-B*5701

- Metabolic panel (creatinine, electrolytes, glucose, liver function tests)

- Hepatitis A IgG

- Hepatitis B sAb, cAb, Ag

- HCV IgG

- STI testing: syphilis test (RPR, VDRL, or treponemal), chlamydia and gonorrhea NAAT tests (urine, pharynx, rectum as indicated by sites of exposure)

- TB screening test (e.g., QuantiFERON)

- Pregnancy test (if appropriate)

- Consider: lipids, G6PD, toxoplasma IgG

Recommended Regimens for Immediate ART

For persons with a new diagnosis of HIV, ART will be started at the first clinic visit, before the results of baseline testing (including HIV RNA, CD4 count, genotype, HLA-B*5701, and creatinine) are available. Thus, the ART regimens must be potent and effective in the setting of high viral load and/or transmitted NRTI and NNRTI resistance mutations (the most frequently transmitted mutations), at least until the lab test results are available. Regimens can be modified, if indicated, based on the genotype results or other results. Regimens also must be simple, easy to take, and have minimal risk of adverse events.

- Bictegravir/TAF/FTC (Biktarvy), 1 po once daily

- Dolutegravir (Tivicay) 50 mg po daily + (TAF/FTC [Descovy], TDF/FTC [Truvada], or TDF/3TC), 1 po once daily

- Darunavir/cobicistat/TAF/FTC (Symtuza), 1 po once daily

Abbreviations: 3TC=lamivudine; FTC=emtricitabine; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate

Other regimens may be appropriate for individual patients.

March 17, 2023

2
For persons who are pregnant, wish to become pregnant, or are at risk of becoming pregnant:
Discuss possible risks and benefits of specific ARVs in pregnancy; select a rapid ART regimen individually, based on shared decision making.

Current HHS perinatal guidelines include:
• Dolutegravir (Tivicay), + (TAF/FTC, TDF/FTC, or TDF/3TC), among their preferred regimens for pregnant persons. (7)

If patient is taking PrEP (pre-exposure prophylaxis) or PEP (post-exposure prophylaxis), or took it at the time of HIV infection or since HIV infection:
• Take a careful history to determine the last time the patient took PrEP or PEP medications
• If there is concern that resistance to the ARVs may have developed, consider a reinforced ART regimen consisting of an integrase inhibitor (dolutegravir or bictegravir) + boosted darunavir + TAF/FTC (or TDF/FTC or TDF/3TC) while awaiting the results of the genotype assay; consult with an expert.

ARVs to AVOID for immediate ART:
• NNRTIs—high risk of transmitted resistance
• Abacavir (including coformulations that contain abacavir)
  - Risk of hypersensitivity reaction if positive for HLA-B*5701
• 2-drug ARV regimens (e.g., dolutegravir + 3TC [Dovato], dolutegravir/raltegravir [Juluca], cabotegravir + rilpivirine [Cabenuva], others)
  - Risk of virologic failure if transmitted resistance to NRTI or NNRTI components is present, risk of virologic failure at high viral load, not studied in immediate ART

Starter packs:
Starter packs containing a 3- to 5-day supply of the selected ART regimen can be helpful if they are available; they ensure that patients can actually start ART on the day of the first clinic visit (by bypassing any delays in obtaining ART because of pharmacy-level issues or snags with insurance activation). They are less important if immediate access to ART can be assured (e.g., via an in-clinic pharmacy).

Follow-Up after Immediate ART Start
Patients started on ART at the first clinic visit often need additional education and extra supports in the days and weeks that follow. Because they have recently been diagnosed with HIV and started on ART with little or no advance preparation, they will need additional HIV-related education, information regarding the importance of medication adherence, counseling about preventing HIV transmission, and encouragement about living healthy lives with HIV.

We recommend scheduling a phone check-in with a social worker, nurse, or clinician 2-3 days after the intake appointment, and a clinic follow-up appointment at 1-2 weeks. The timing of subsequent visits will depend on the needs of the patient, but in general, the next appointment should take place within 1 month of the start of ART and at least monthly thereafter until the HIV viral load is suppressed and the patient is well engaged in care.

At the follow-up appointment, clinicians should review baseline lab results with the patient, evaluate ART adherence, screen for side effects, and provide further counseling and education. When the genotype result is available, the clinician can make decisions about whether a change in ART is indicated, though unnecessary changes generally should be avoided.

Immediate ART Restart for Persons Returning to Care
While a key goal of HIV care is for people with HIV (PWH) to achieve continuous viral suppression on ART, in actuality many PWH may stop ART or fall out of care for periods of time. It is important to reengage these patients in care at the earliest opportunity, and to support them in restarting ART.

For these patients, we recommend immediate ART restart (or initial start, if not previously on ART) at the first reengagement visit if the patient is willing. Immediate restart is particularly important if the CD4 count is <200 cells/mm3.

Immediate ART restart is appropriate for:
• Nearly all PWH who are reengaging in care
• PWH for whom the ART history is known, and HIV resistance is known or can be predicted (based on previous resistance testing, HIV viral load while on ART, and adherence history)
• An appropriate ART regimen can be devised without information from current resistance test results.

Immediate ART restart is not appropriate for:
• Persons with certain untreated opportunistic infections (OIs), e.g., CNS OIs, for whom a short period of treatment for the OI is recommended before ART initiation.
• An appropriate ART regimen cannot be devised without information from current resistance test results.
• Continuing education about HIV, the benefits of ART (including the importance of adherence and viral suppression) for personal health and for preventing transmission to others
• Obtaining buy-in from the patient to restart ART immediately
• Engaging the patient to return to clinic for follow-up appointments

Patients who are reengaging in care should receive enhanced clinical supports to optimize the likelihood of successful reengagement in care and adherence with ART. This includes same-day evaluation by a social worker or counselor; insurance enrollment or optimization; referral for mental health, substance use, or other services as needed; and close follow up with the primary care provider.

Laboratory Testing

• HIV RNA (viral load)
• CD4 cell count
• HIV resistance test: generally, a genotype (including integrase if past ART included an integrase inhibitor)
  - A resistance test may not be needed if new acquired resistance is unlikely (e.g., for patients who had viral suppression at the time they discontinued ART).
  - Resistance test results may not detect mutations if the patient has been off ART for about 4 weeks or more – consult with an expert
• Creatinine, liver transaminases
• Other tests as indicated or if not previously done (see Baseline laboratory testing, above)

ART Regimens for Immediate Restart

Regimens should be selected individually, based on the patient’s specific HIV, ART, and resistance history; as well as their comorbidities, tolerance of previous ARVs, adherence challenges, and other factors. Consult with an HIV expert.

It is not possible to make recommendations for individual patients, but common ART restart scenarios include:
• The patient was taking a 1st or 2nd ART regimen and there is no suspected resistance: can start one of the regimens for initial immediate ART (e.g., bictegravir/TAF/FTC or dolutegravir + TAF/FTC), or (unless contraindications) can restart the patient’s previous regimen.
• The patient has a known or suspected history of virologic failure with acquired ART resistance: select the ART regimen based on the suspected resistance mutations.

- If there is concern for NRTI and/or NNRTI resistance, consider a boosted protease inhibitor + 2 NRTIs +/- an integrase inhibitor (e.g., darunavir/cobicistat/TAF/FTC + dolutegravir).
- If there is concern for NRTI and/or INSTI resistance, consider a boosted protease inhibitor + 2 NRTIs +/- a 2nd generation NNRTI (if no history of treatment with an NNRTI) (e.g., darunavir/cobicistat/TAF/FTC + doravirine).
- If more extensive resistance may be present, consider a multi-class regimen with a boosted darunavir + an integrase inhibitor +/- an NNRTI +/- fostemsavir or other ARVs as indicated.

For persons who are pregnant or who may become pregnant on a rapidly restarted regimen:
• Certain ARVs are not recommended during pregnancy. Providers should discuss possible risks and benefits of ARVs with persons who are pregnant or may become pregnant and select ARVs through shared decision making.

The following generally should NOT be prescribed for immediate ART restart:
• 2-ARV regimens, e.g., dolutegravir/3TC (Dovato), dolutegravir/ rilpivirine (Juluca), cabotegravir + rilpivirine [Cabenuva], others (high risk of virologic failure if resistance is present; some studied only for ART switch in persons with suppressed HIV viral load)
• Abacavir, unless HLA B5701 is known to be negative

Persons who decline immediate ART restart

Reengaging patients who decline immediate restart (or who are not restarted for other reasons) should be followed closely (e.g., in 1-2 weeks) and restarted at the earliest appropriate time.

Consult with experts

Clinical questions frequently arise in the evaluation and management of persons with new HIV diagnoses. These include uncertainties about interpretation of discordant HIV test results, risk of transmitted or acquired drug resistance, and decisions about which ART regimens to start. Clinicians should seek expert consultation if they have questions or concerns.

The National Clinician Consultation Center, a component of HRSA’s AIDS Education and Training Center (AETC) Program, provides free phone consultation on immediate ART through its HIV/AIDS Management call line (800-933-3413, Monday-Friday 9 am-8 pm ET) and Perinatal HIV hotline (888-448-8765, 24 hours a day).
References


